Teva Pharmaceutical Industries (TEVA) EPS (Basic) (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported EPS (Basic) for 18 consecutive years, with -$0.49 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EPS (Basic) fell 301.82% year-over-year to -$0.49; the trailing twelve-month figure through Jun 2026 stood at $0.6 (up 510.33% YoY), and the FY2025 full-year result was $1.23, up 170.71% from the prior year.
• EPS (Basic) eased to -$0.49 in Q2 2026 per TEVA's latest filing, from $0.32 in the prior quarter.
• Across five years, EPS (Basic) topped out at $0.46 in Q1 2024 and bottomed at -$1.2 in Q4 2022.
• Historically, EPS (Basic) has averaged -$0.15 across 5 years, with a median of -$0.08 in 2022.
• The sharpest annual moves came in 2022 and 2024: EPS (Basic) tumbled 1278.01% in 2022, then surged 303.68% in 2024.
• Over 5 years, EPS (Basic) stood at -$1.2 in 2022, then soared by 134.65% to $0.42 in 2023, then plunged by 158.39% to -$0.24 in 2024, then jumped by 268.82% to $0.41 in 2025, then plunged by 220.45% to -$0.49 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.49, $0.32, and $0.41 for Q2 2026, Q1 2026, and Q4 2025 respectively.